### Financial Performance Snapshot

<table>
<thead>
<tr>
<th></th>
<th>2Q19 As Reported</th>
<th>2Q18 Pro Forma</th>
<th>B / (W)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net Sales ($M)</td>
<td>5,468</td>
<td>5,857</td>
<td>(389)</td>
</tr>
<tr>
<td>Operating EBITDA(^1) ($M)</td>
<td>1,422</td>
<td>1,422</td>
<td>0</td>
</tr>
</tbody>
</table>

**YoY Net Sales Change:** Volume: (5%), Local Price: 2%, Currency: (3%), Portfolio / Other: (1%)

### Key Factors

- Organic net sales change of (3%)
  - U.S. & Canada – (2%)
  - EMEA – (3%)
  - Asia Pacific – (4%)
  - Latin America – 1%

- 8\(^{th}\) consecutive quarter of price improvement
  - Pricing gains in all regions
  - Pricing gains in most segments (flat in E&I and Non-Core)

- Operating EBITDA\(^1\) margin expansion of 170 basis points
  - Led by gross margin improvement in all core segments
  - Operating EBITDA margins at 26%

- Delivered strong operating leverage; flat earnings on 7% decline in net sales

\(^1\) Operating EBITDA is a non-GAAP measure. See page 16 for further discussion.
2Q 2019 Financial Highlights, continued

Adjusted Earnings Per Share\(^{(1)}\) (EPS) Variance

- $0.00
- $0.04
- $0.03
- $0.02
- $(0.01)
- $0.97 \(+9\%\)

Segment Results:
- 2Q ‘18 Pro Forma Adjusted EPS\(^{(1)}\)

D&A:
- $0.04

Share Count:
- $0.03

Tax:
- $0.02

NCI:
- $(0.01)

2Q ‘19 Adjusted EPS\(^{(1)}\):
- $0.97

Key Factors:
- EBITDA improvement in S&C, N&B, and Corporate offset by declines in other segments primarily driven by short-cycle exposure.
- Depreciation and amortization lower due to the absence of depreciation from heritage Dow corporate assets.
- Lower share count driven by share repurchase activity under DowDuPont.

\(^{(1)}\) Adjusted EPS and pro forma adjusted EPS are non-GAAP measures. See page 16 for further discussion.
## 3Q and FY 2019 Outlook

<table>
<thead>
<tr>
<th></th>
<th>3Q 2019E</th>
<th>Previous FY 2019E</th>
<th>Current FY 2019E</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net Sales</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>YOY Organic Growth</td>
<td>Down</td>
<td>Up 2-3%</td>
<td>Slightly Down</td>
</tr>
<tr>
<td></td>
<td>Low-Single Digits</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Adjusted EPS(^{(1)})</strong></td>
<td>$0.94 - $0.99</td>
<td>$3.70 - $3.85</td>
<td>$3.75 - $3.85</td>
</tr>
</tbody>
</table>

\(^{(1)}\) Adjusted EPS (3Q 2019E) and pro forma adjusted EPS (FY 2019E) are non-GAAP measures. See page 16 for further discussion.
2Q 2019 Segment Results

Net Sales
Organic Growth

- **Electronics & Imaging**: $858 million (5%) YOY
- **Nutrition & Biosciences**: $1,558 million Flat YOY
- **Transportation & Industrial**: $1,269 million (7%) YOY
- **Safety & Construction**: $1,341 million 5% YOY
- **Non-Core**: $442 million (14%) YOY

Operating EBITDA Margin
YOY Change

- **Electronics & Imaging**: 28.7% (280 bps)
- **Nutrition & Biosciences**: 25.1% +150 bps
- **Transportation & Industrial**: 28.1% (30 bps)
- **Safety & Construction**: 28.5% +690 bps
- **Non-Core**: 22.4% (100 bps)
Volume gains in Display Technologies were more than offset by softer volumes in Semiconductor Technologies and Interconnect Solutions.

- Display Technologies volume gains were led by double-digit growth in OLEDs.
- Semiconductor Technologies—weak demand due to high inventory levels in the memory sector more than offset double-digit growth in semiconductor packaging.
- Interconnect Solutions—demand for advanced materials for next-generation smartphones remained strong. Despite this strength, overall volume in Interconnect Solutions was down mid-single digits due to soft circuit board demand.

Operating EBITDA for the segment was down 15 percent. Lower volumes and an unfavorable product mix more than offset cost synergies.
Nutrition & Biosciences

2Q Net Sales

Vol -1%, Local Price 1%, Currency -3%, Portfolio -1%

<table>
<thead>
<tr>
<th>2Q18</th>
<th>Volume</th>
<th>Local Price</th>
<th>Currency</th>
<th>Portfolio</th>
<th>2Q19</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,621</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1,558</td>
</tr>
</tbody>
</table>

2Q Operating EBITDA

<table>
<thead>
<tr>
<th>$ in Millions</th>
</tr>
</thead>
<tbody>
<tr>
<td>2Q18</td>
</tr>
<tr>
<td>$383</td>
</tr>
</tbody>
</table>

2Q 2019 Highlights

- Volume gains in Health & Biosciences were more than offset by softer volumes in Food & Beverage and Pharma Solutions.
  - Health & Biosciences volume gains were led by double-digit growth in probiotics and mid-single digit growth in microbial control, offset by lower bioactives volumes.
  - Food & Beverage volumes were lower versus the year-ago period, with gains in specialty proteins driven by growing demand in plant-based meats more than offset by declines in functional solutions driven by unseasonably cooler weather impacting our dairy volumes.
  - Pharma Solutions volumes declined low-single digits versus the year-ago period due to capacity constraints, mix enrichment as we shift the portfolio towards higher-margin products and a strong comparison in the prior year.
  - Local price improved across all businesses in the quarter.

- Operating EBITDA for the segment was $391 million. Cost synergies and pricing gains were partially offset by higher raw materials costs, currency headwinds and the impact of lower volumes.
Transportation & Industrial

2Q Net Sales
Vol -12%, Local Price 5%, Currency -3%, Portfolio 0%

$ in Millions

<table>
<thead>
<tr>
<th></th>
<th>2Q18</th>
<th>2Q19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>1,417</td>
<td>1,269</td>
</tr>
<tr>
<td>Local Price</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Currency</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Portfolio</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2Q Operating EBITDA

$ in Millions

<table>
<thead>
<tr>
<th></th>
<th>2Q18</th>
<th>2Q19</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>402</td>
<td>357</td>
</tr>
</tbody>
</table>

2Q 2019 Highlights

- Volume declined 12 percent due to lower autobuilds versus the year-ago period, weak electronics demand and continued de-stocking in both the automotive and electronics channels.
- Europe and Asia volumes were down mid-teens as tariff concerns coupled with inventory destocking reduced demand.
- Local price improved across all regions and businesses in the quarter.
- Operating EBITDA for the segment was $357 million. Pricing gains and cost synergies were more than offset by the impact from lower volume and currency headwinds.
Safety & Construction

2Q Net Sales
Vol 1%, Local Price 4%, Currency -3%, Portfolio -4%

2Q 2019 Highlights
- Local price increased across all businesses and in all regions, led by Safety and Water Solutions.
- High-single digit volume gains in the Water Solutions business were mostly offset by lower volumes in the Shelter Solutions business on continued softness in North America residential construction demand.
- Safety Solutions volumes were flat with the year-ago period driven by capacity constraints in Tyvek® and aramid product lines.
- Operating EBITDA for the segment totaled $382 million led by strength in the Water and Safety Solutions businesses driven by local price gains, cost synergies, and productivity improvements more than offsetting a currency headwind.
Balance Sheet and ROIC

**Balance Sheet**

- $15.6 billion net debt at June 30, 2019
  - Excludes $1.0B unfunded pension liability
- Expected uses of cash for 2H 2019 (transaction-related)
  - Transaction and restructuring costs ~ $0.3B
  - Pension funding (Switzerland) ~ $0.2B
  - CapEx ~$0.2B
- Working capital
  - Higher ending A/R balances driven by system cut-over and stand-up process
  - $1 billion multi-year opportunity in working capital improvement

**Return On Invested Capital**

- On track for 200 bps improvement from 2017; in-line with target
- Disciplined approach to CapEx and R&D spending
- Excess cash returned to shareholders
- Management incentive programs aligned to key metrics, including ROIC improvement

---

(1) September 2018, December 2018 and March 2019 balances are on a pro forma basis. See page 16 for further discussion.
2019 Priorities Focused On Shareholder Value Creation

- **Drive top line growth through innovation and pricing discipline**
  - 8th consecutive quarter of pricing gains mitigates impact of softer volumes
  - New products accelerating growth in automotive electrification, healthcare, 5G, clean water and sustainable food platforms

- **Expand margins through strong productivity focus and synergy capture**
  - ~$100 million incremental cost synergies delivered in the quarter; $450 million expected for 2019
  - Focus shifting towards on-going productivity to achieve leverage targets

- **Continue to execute portfolio actions and upgrades**
  - Divestiture process for non-core assets underway
  - Optionality of DuPont portfolio provides attractive alternatives for value creation

- **Enable strong cash generation through earnings growth and working capital productivity**
  - Current year cash needs for transaction costs, restructuring costs and completion of capital structure
  - Continue to expect free cash flow conversion > 90% over medium-term

- **Continue to improve ROIC through effective capital allocation and R&D spend**
  - $2 billion share repurchase program announced at time of stand-up; $250 million repurchased to date
  - CapEx and R&D spend on-track to be within annual targets
Appendix
### 3Q and FY 2019E Segment Guidance

<table>
<thead>
<tr>
<th>Segment</th>
<th>3Q Net Sales</th>
<th>3Q Working Income</th>
<th>Full-Year 2019 Net Sales</th>
<th>Full-Year 2019 EBITDA</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Electronics &amp; Imaging</strong></td>
<td>flat</td>
<td>flat</td>
<td>flat</td>
<td>down</td>
</tr>
<tr>
<td><strong>Nutrition &amp; Biosciences</strong></td>
<td>flat</td>
<td>up in single digits</td>
<td>flat</td>
<td>up in low single digits</td>
</tr>
<tr>
<td><strong>Transportation &amp; Industrial</strong></td>
<td>down in teens percent</td>
<td>down in low single digits</td>
<td>down high single digits</td>
<td>down high single digits</td>
</tr>
<tr>
<td><strong>Safety &amp; Construction</strong></td>
<td>flat</td>
<td>up in single digits</td>
<td>flat</td>
<td>up in single digits</td>
</tr>
<tr>
<td><strong>Non-Core</strong></td>
<td>down in teens percent</td>
<td>down high single digits</td>
<td>down high single digits</td>
<td>down about thirty percent</td>
</tr>
</tbody>
</table>

- **3Q Net Sales**: expected to be down low-teens percent versus the prior year on an as reported and organic basis on lower volumes partially offset by higher local price. Portfolio is expected to reduce sales by 2 to 3 percent. 3Q operating EBITDA is expected to be up low-thirties percent on higher earnings from an equity affiliate including an expected customer settlement.
- **Full-Year 2019**: Net Sales expected to be down low-teens percent on an as reported basis and down high-single digits organically on lower volumes. Portfolio is expected to reduce sales by mid-single digits. Operating EBITDA is expected to be down about thirty percent for the year on lower earnings from an equity affiliate.
### Additional Modeling Guidance – 3Q19E

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Base Tax Rate</td>
<td>20% - 22%</td>
</tr>
<tr>
<td>Share count – diluted</td>
<td>~747 million</td>
</tr>
<tr>
<td>D&amp;A – Includes Merger-Related Amortization</td>
<td>~$515 million, pre tax</td>
</tr>
<tr>
<td>Merger-Related Amortization</td>
<td>~$200 million, pre tax</td>
</tr>
<tr>
<td>Interest Expense, net</td>
<td>~$175 million, pre tax</td>
</tr>
<tr>
<td>Exchange (Gains)/Losses</td>
<td>~$30 million, pre tax</td>
</tr>
<tr>
<td>Non-Controlling Interest</td>
<td>~$10 million, after tax</td>
</tr>
</tbody>
</table>

### Additional Modeling Guidance – FY19E

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Base Tax Rate</td>
<td>20% - 22% (vs. 17% for 2018)</td>
</tr>
<tr>
<td>Share count – diluted</td>
<td>~747 million</td>
</tr>
<tr>
<td>D&amp;A – Includes Merger-Related Amortization</td>
<td>~$2,065 million, pre tax</td>
</tr>
<tr>
<td>Merger-Related Amortization</td>
<td>~$800 million, pre tax</td>
</tr>
<tr>
<td>Interest Expense, net</td>
<td>~$650 million, pre tax</td>
</tr>
<tr>
<td>Exchange (Gains)/Losses</td>
<td>~$140 million, pre tax</td>
</tr>
<tr>
<td>Non-Controlling Interest</td>
<td>~$35 million, after tax</td>
</tr>
</tbody>
</table>
Safe Harbor Statement

Cautionary Statement Regarding Forward Looking Statements

This communication contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," "target," and similar expressions and variations or negatives of these words.

On April 1, 2019, the company completed the separation of its materials science business into a separate and independent public company by way of a pro rata dividend-in-kind of all the then outstanding stock of Dow Inc. (the "Dow Distribution"). The company completed the separation of its agriculture business into a separate and independent public company on June 1, 2019, by way of a pro rata dividend-in-kind of all the then outstanding stock of Corteva, Inc. (the "Corteva Distribution").

Forward-looking statements address matters that are, to varying degrees, uncertain and subject to risks, uncertainties and assumptions, many of which are beyond DuPont's control, that could cause actual results to differ materially from those expressed in any forward-looking statements. Forward-looking statements are not guarantees of future results. All statements about guidance, outlook and estimates, including, for the third quarter 2019, full year 2019, additional guidance and any statements denoted by "2019E" are forward-looking statements. Some of the important factors that could cause DuPont's actual results to differ materially from those projected in any such forward-looking statements include, but are not limited to: (i) ability and costs to achieve all the expected benefits from the Dow Distribution and the Corteva Distribution (together, the "Distributions"); (ii) constraints on DuPont's ability to take strategic action concerning certain levels of assets and businesses under an agreement entered into in connection with the Corteva Distribution; (iii) restrictions under intellectual property cross license agreements entered into in connection with the Distributions; (iv) non-compete restrictions agreed in connection with the Distributions; (v) the incurrence of significant costs in connection with the Distributions, including costs to service debt incurred by the company to establish the relative credit profiles of Corteva, Dow and DuPont and increased costs related to supply, service and other arrangements that, prior to the Dow Distribution, were between entities under the common control of DuPont; (vi) risks related to indemnification obligations of Historical DuPont contingent liabilities in connection with the Corteva Distribution (vii) potential liability arising from fraudulent conveyance and similar laws in connection with the Distributions; (viii) disruptions or business uncertainty, including from the Distributions, could adversely impact DuPont's business, or financial performance and its ability to retain and hire key personnel; (ix) uncertainty as to the long-term value of DuPont common stock; (x) potential inability or reduced access to the capital markets or increased cost of borrowings, including as a result of a credit rating downgrade; (xi) uncertainties related to share buybacks including costs, time and ability to complete; and (xii) risks to DuPont's business, operations and results of operations from: failure to develop and market new products and optimally manage product life cycles; ability, cost and impact on business operations, including the supply chain, of responding to changes in market acceptance, rules, regulations and policies and failure to respond to such changes; outcome of significant litigation, environmental matters and other commitments and contingencies; failure to appropriately manage process safety and product stewardship issues; global economic and capital market conditions, including the continued availability of capital and financing, as well as inflation, interest and currency exchange rates; impairment of goodwill or intangible assets especially as to those assets that were stepped up at September 1, 2017 based on merge-related acquisition method of accounting; changes in political conditions, including tariffs, trade disputes and retaliatory actions; the availability of and fluctuations in the cost of raw materials and energy; business or supply disruptions; security threats, such as acts of sabotage, terrorism or war, natural disasters and weather events and patterns which could result in a significant operational event for DuPont, adversely impact demand or production; ability to discover, develop and protect new technologies and to protect and enforce DuPont's intellectual property rights; failure to effectively manage acquisitions, divestitures, alliances, joint ventures and other portfolio changes; unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as management's response to any of the aforementioned factors. These risks are and will be more fully discussed in DuPont's current, quarterly and annual reports and other filings made with the U.S. Securities and Exchange Commission, in each case, as may be amended from time to time in future filings with the SEC. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on DuPont's consolidated financial condition, results of operations, credit rating or liquidity. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. DuPont assumes no obligation to publicly provide revisions or updates to any forward-looking statements whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements is included in the section titled "Risk Factors" (Part I, Item 1A) of the company's 2018 Annual Report on Form 10-K as modified by its 2019 quarterly reports on Form 10-Q and current reports on Form 8-K.
Safe Harbor Statement

Cautionary Statement About Forward-Looking Statements, continued

Unaudited Pro Forma Financial Information:
The unaudited pro forma financial information (the “pro forma financial statements”) is derived from DuPont’s Consolidated interim Financial Statements and accompanying notes, adjusted to give effect to certain events directly attributable to the Distributions and Financings (as defined below). In contemplation of the Distributions and to achieve the respective credit profiles of each of DuPont, Dow, and Corteva, in the fourth quarter of 2018, DowDuPont consummated a public underwritten offer of eight series of senior unsecured notes (the “2018 Senior Notes”) in the aggregate principal amount of $12.7 billion and entered into a term loan agreement consisting of two term loan facilities (the “Term Loan Facilities”) in the aggregate principal amount of $3.0 billion. In May 2019, the funds from the Term Loan Facilities were drawn, along with the issuance of approximately $1.4 billion in commercial paper (the “Funding CP Issuance” together with the 2018 Senior Notes and Term Loan Facilities, the “Financings”). The net proceeds from the Financings together with cash from operations were used to fund cash contributions to Dow and Corteva, and DowDuPont’s $3.0 billion share repurchase program which was completed in the first quarter of 2019 (the “Share Repurchase Program”). The unaudited pro forma financial statements were prepared in accordance with Article 11 of Regulation S-X. The historical consolidated financial information has been adjusted to give effect to pro forma events that are (1) directly attributable to the Distributions and the Financings (collectively the “Transactions”), (2) factually supportable and (3) with respect to the interim Statements of Operations, expected to have a continuing impact on the results. The unaudited pro forma statements of operations for the six months ended June 30, 2019 and for three and six months ended June 30, 2018 give effect to the pro forma events as if they had been consummated on January 1, 2018. There were no pro forma adjustments for the three months ended June 30, 2019. Restructuring or integration activities or other costs following the Distributions that may be incurred to achieve cost or growth synergies of DuPont are not reflected. The pro forma financial statements provide shareholders with summary financial information and historical data that is on a basis consistent with how DuPont reports current financial information. The unaudited pro forma financial statements are presented for informational purposes only, and do not purport to represent what DuPont’s results of operations or financial position would have been had the Transactions occurred on the dates indicated, nor do they purport to project the results of operations or financial position for any future period or as of any future date.

Non-GAAP Financial Measures:
This presentation includes information that does not conform to accounting principles generally accepted in the United States of America (“U.S. GAAP”) and are considered non-GAAP measures. Management uses these measures internally for planning, forecasting and evaluating the performance of the Company, including allocating resources. DuPont’s management believes these non-GAAP financial measures are useful to investors because they provide additional information related to the ongoing performance of DuPont to offer a more meaningful comparison related to future results of operations. These non-GAAP financial measures supplement disclosures prepared in accordance with U.S. GAAP, and should not be viewed as an alternative to U.S. GAAP. Furthermore, such non-GAAP measures may not be consistent with similar measures provided or used by other companies. Reconciliations for these non-GAAP measures to U.S. GAAP are provided in the Selected Financial Information and Non-GAAP Measures starting on page 16. Non-GAAP measures included in this release are defined as follows: Pro forma adjusted earnings per common share from continuing operations - diluted, is defined as pro forma earnings per common share from continuing operations - diluted, excluding the after-tax impact of significant items, after-tax impact of amortization expense associated with intangibles acquired as part of the Merger, after-tax impact of non-operating pension / other post employment benefits ("OPEB") / charges, and after-tax impact of costs historically allocated to the materials science and agriculture businesses that did not meet the criteria to be recorded as discontinued operations. Adjusted earnings per common share from continuing operations - diluted, is defined as earnings per common share from continuing operations - diluted, excluding the after-tax impact of significant items, after-tax impact of amortization expense associated with intangibles acquired as part of the Merger, after-tax impact of non-operating pension / other post employment benefits ("OPEB") / charges, and after-tax impact of costs historically allocated to the materials science and agriculture businesses that did not meet the criteria to be recorded as discontinued operations. Pro forma operating EBITDA, is defined as earnings (i.e. pro forma income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, non-operating pension / OPEB benefits / charges, and foreign exchange gains / losses, excluding the impact of costs historically allocated to the materials science and agriculture businesses that did not meet the criteria to be recorded as discontinued operations and excluding significant items. Operating EBITDA, is defined as earnings (i.e. income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, nonoperating pension / OPEB benefits / charges, and foreign exchange gains / losses, excluding the impact of costs historically allocated to the materials science and agriculture businesses that did not meet the criteria to be recorded as discontinued operations and excluding significant items. Organic Sales is defined as net sales excluding the impacts of currency and portfolio.